Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms PALACE-1
- Sponsors Amgen; Celgene Corporation
- 15 Nov 2023 Results assessing the effects of apremilast on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis from 5 studies PALACE 1-4 and ACTIVE, presented at the ACR Convergence 2023.
- 03 Jun 2023 Results of pooled analysis from PALACE 1 and 2 ; assessing the impact of APR on PsA disease domains in patients with BSA less than 3% vs BSA greater than 3% at 52 weeks, presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results of pooled analysis (n=781 from studies PALACE 1 to 4 and ACTIVE) assessing the effects of APR on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis presented at the 24th Annual Congress of the European League Against Rheumatism